The riddle of psychiatric disorders in parkinson disease: From phenomenology to treatment

American Journal of Geriatric Psychiatry

Volumn 20, Issue 2, 2012, Pages 99-103

  Starkstein, Sergio E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; OLANZAPINE; QUETIAPINE; RISPERIDONE; SELEGILINE;

ALEXITHYMIA; APATHY; CAUSE OF DEATH; COMORBIDITY; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EMBRYO MORTALITY; HUMAN; MENTAL DISEASE; PARKINSON DISEASE; PARKINSONISM; PRACTICE GUIDELINE; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; STRUCTURED INTERVIEW;

EID: 84856235926     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e318240f90a     Document Type: Editorial

References (30)

1. Andriole GL, Crawford ED, Grubb RL III, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-1319
2. Driver JA, Logroscino G, Gaziano JM, et al: Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009; 72:432-438
3. Louis ED, Bennett DA: Mild parkinsonian signs: an overview of an emerging concept. Mov Disord 2007; 22:1681-1688 (Pubitemid 47597591)
4. Mack JL, Rabins PV, Anderson K, et al: Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry 2012; 20:123-131
5. Assogna F, Palmer K, Pontieri FE, et al: Alexithymia is a non-motor symptom of Parkinson disease. Am J Geriatr Psychiatry 2012; 20:133-141
6. Pedersen KF, Alves G, Larsen JP, et al: Psychometric properties of the Starkstein Apathy Scale in patients with early untreated Parkinson disease. Am J Geriatr Psychiatry 2012; 20:142-148
7. Marras C, Gruneir A, Wang X, et al: Antipsychotics and mortality in Parkinsonism. Am J Geriatr Psychiatry 2012; 20:149-158
8. Fernandez HH, Aarsland D, Fenelon G, et al: Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord 2008; 23:484-500
9. Weintraub D, Burn DJ: Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord 2011; 26:1022-1031
10. Ravina B, Marder K, Fernandez HH, et al: Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007; 22:1061-1068 (Pubitemid 47067214)
11. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al: A 12-year populationbased study of psychosis in Parkinson disease. Arch Neurol 2010; 67:996-1001
12. Fenelon G, Soulas T, de Langavant LC, et al: Feeling of presence in Parkinson's disease. J Neurol Neurosurg Psychiatry 2011; 82:1219-1224
13. Fenelon G, Goetz CG, Karenberg A: Hallucinations in Parkinson disease in the prelevodopa era. Neurology 2006; 66:93-98 (Pubitemid 43739599)
14. Goetz CG, Pappert EJ, Blasucci LM, et al: Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998; 50:515-517 (Pubitemid 28119803)
15. Miyasaki JM, Shannon K, Voon V, et al: Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:996-1002 (Pubitemid 44044781)
16. Weintraub D, Chen P, Ignacio RV, et al: Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 2011; 68:899-904
17. Eng ML, Welty TE: Management of hallucinations and psychosis in Parkinson's disease. Am J Geriatr Pharmacother 2010; 8:316-330
18. Pollak P, Tison F, Rascol O, et al: Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75:689-695 (Pubitemid 38526677)
19. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934-1943 (Pubitemid 41464695)
20. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al: What predicts mortality in Parkinson disease? A prospective population-based longterm study. Neurology 2010; 75:1270-1276
21. Sifneos PE: The prevalence of "alexithymic" characteristics in psychosomatic patients. Psychother Psychosom 1973; 22:255-262
22. Taylor GJ: Alexithymia: concept, measurement, and implications for treatment. Am J Psychiatry 1984; 141:725-732 (Pubitemid 14106355)
23. Bagby RM, Parker JD, Taylor GJ: The twenty-item Toronto Alexithymia Scale-I. Item selection and cross-validation of the factor structure. J Psychosom Res 1994; 38:23-32
24. Bennett MR, Hacker PMS: Philosophical Foundations of Neuroscience. Malden, MA, Blackwell, 2003
25. Marin RS: Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3:243-254
26. Starkstein SE: Apathy and withdrawal. Int Psychogeriatr 2000; 12:135-138
27. Robert P, Onyike CU, Leentjens AF, et al: Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 2009; 24:98-104
28. Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991; 38:143-162
29. Starkstein SE, Mayberg HS, Preziosi TJ: Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4:134-139
30. Starkstein S, Merello M, Jorge R, et al: The syndromal validity and nosological position of apathy in Parkinson's disease. Mov Disord 2009; 15:1211-1216